Understanding hepatitis B virus inhibitor, Clevudine transport in human blood circulation: An in vitro albumin binding study

Title : Understanding hepatitis B virus inhibitor, Clevudine transport in human blood circulation: An in vitro albumin binding study

Abstract:

Hepatitis B, a viral infection that can cause both acute and chronic hepatitis, cirrhosis and hepatocellular carcinoma, is a major global health issue. Hepatocellular carcinoma is one of the most common types of cancer, accounting for roughly 90% of all primary liver tumours.  The virus replication is through reverse transcription and most antiviral drugs are nucleoside/nucleotide analogues.  Clevudine, a nucleoside analogue licenced in Korea in 2006 has been found effective in controlling HBV infection. Interaction between a dug and the plasma protein is of pharmacological significance as this interaction could affect drug absorption, distribution, metabolism and excretion in the body as well as the physiological activity of the protein. Understanding such interactions offer information about drug-drug interaction, and drug-protein resistance and is helpful to predict potential drug dosages and adverse effects. Serum albumin, a 585 residue-long protein encompassing three domains, I, II and III with their divisions into two subdomains, A and B,  is the main drug transporter in blood circulation. It possesses two well-defined drug-binding sites, namely, Site I (subdomain IIA) and Site II (subdomain IIIA). This talk will highlight the interaction results between clevudine and human serum albumin using a variety of spectroscopic techniques i.e.,   absorption, fluorescence, circular dichroism and atomic force microscopy along with molecular docking.   

Biography:

Dr. Saad Tayyab studied Biochemistry at Aligarh Muslim University, India, completing Masters and Ph.D. degrees in 1981 and 1987, respectively. He is currently working as a Professor of Pharmaceutical Chemistry at UCSI University, Kuala Lumpur, Malaysia. Before joining UCSI University, Dr. Saad served at Universiti Malaya (2004-2018), Haramaya University, Ethiopia (2001-2004), Aligarh Muslim University, India (1988-2001), and the University of Kashmir, India (1987-1988). He was admitted as a Fellow, Royal Society of Chemistry, UK, in 2017, Fellow, Royal Society of Biology, UK, in 2019, Member, American Chemical Society in 2020, and Member, Sigma Xi in 2024. He is serving as an Editorial Board member for several journals. He has published over 150 journal papers, 17 popular articles, 1 book, 2 book chapters, and 1 learning aid. Several research students (16 Ph.D., 6 M.Phil., 1 M.D., and 13 M.Sc.) completed their degrees under his supervision, and he guided 32 undergraduate projects. His research interests include drug-protein interaction, protein folding, protein/enzyme stability, and protein structure-function. He possesses an h-index of 27, and his name is included in the reviewers’ lists of many international journals.